Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00576589 · ClinicalTrials.gov registry record · Phase 1
Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00576589 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 41 participants.
The verdict
NCT00576589, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The study is designed to assess whether repeated dosing with CE-326,597 will cause patients with asymptomatic gallstones (as detected on screening abdominal ultrasound) to become symptomatic. In addition, the study will characterize the pharmacokinetics of CE-326,597.
Interventions
- DRUG Placebo
- DRUG CE-326,597
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00576589
The ClinicalTrials.gov registry entry for NCT00576589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00576589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00576589 about?
NCT00576589 is a clinical study titled "Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones". The study is designed to assess whether repeated dosing with CE-326,597 will cause patients with asymptomatic gallstones (as detected on screening abdominal ultrasound) to become symptomatic. In addition, the study will characterize the pharmacokinetics of CE-326,597.
What is the current status of trial NCT00576589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2008-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00576589?
The interventions under investigation include: Placebo (DRUG), CE-326,597 (DRUG).
Who is sponsoring clinical trial NCT00576589?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.